Related references
Note: Only part of the references are listed.Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation
Laurie H. Sehn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
Antonio Gualberto
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Ivana N. M. Micallef et al.
BLOOD (2011)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart
CLINICAL CANCER RESEARCH (2011)
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
Sara Raponi et al.
LEUKEMIA & LYMPHOMA (2011)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
Michinori Ogura et al.
CANCER SCIENCE (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
A. G. Polson et al.
LEUKEMIA (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
Hans-Peter Gerber et al.
BLOOD (2009)
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
David Dornan et al.
BLOOD (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
Andrew G. Polson et al.
CANCER RESEARCH (2009)
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates
Bing Zheng et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Contribution of linker stability to the activities of anticancer immunoconjugates
Stephen C. Alley et al.
BIOCONJUGATE CHEMISTRY (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
Ezogelin Oflazoglu et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
J. F. DiJoseph et al.
LEUKEMIA (2007)
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Andrew G. Polson et al.
BLOOD (2007)
CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab
John F. DiJoseph et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
Sandra J. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety of rituximab maintenance therapy in follicular lymphomas
P Solal-Céligny
LEUKEMIA RESEARCH (2006)
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry
SH Olejniczak et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
JF DiJoseph et al.
CLINICAL CANCER RESEARCH (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Mechanisms of disease: Acute lymphoblastic leukemia
C Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
JP Leonard et al.
CLINICAL CANCER RESEARCH (2004)
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
CL Law et al.
CLINICAL CANCER RESEARCH (2004)
Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation
R Arens et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium
K Margolin et al.
INVESTIGATIONAL NEW DRUGS (2001)
Share Paper
